Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Roland Utz

Hans-Jochen Lang

Bernward Scholkens

Heinrich Christian Englert

Karl Geisen

Heiner Glombik

Wilfried Schwab

Andreas W Herling

Dieter Mania

Peter Schindler

Horst Hemmerle

Robert Rippel

Erik Klaus

Hildegard Nimmesgern

Jochen Hachtel

Bernd Neises

Martin Zahn

Friedrich E Beyhl

A process is described for producing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamide, in which a phenyl-substituted 2-cyano-N-(phenyl)acetamide is reacted in the presence of a base, acetic anhydride and at least one solvent, and the resultant 2-cyano-3-hydroxy-N-(phenyl-derivative)but-2-enamide is crystallized by acidification.

Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides

Substituted cyclohexane derivatives for the treatment of diseases Esters of cyclohexane derivatives of the formula I ##STR1## in which A--B, R.sup.3, R.sup.4, R.sup.5, Y and Z have the meanings indicated, for use as inhibitors of the glucose-6-phosphatase system of the liver in mammals are described. The compounds are suitable for the production of pharmaceutical preparations.

Substituted cyclohexane derivatives for the treatment of diseases

Pyrimidine derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2, X and Y have the stated meaning, the salts thereof and a process for the preparation thereof are described. Because of their sorbitol-accumulating activity, they are suitable for use as reagents for an advantageous pharmacological screening model for testing aldose reductase inhibitors.

Substituted pyrimidine derivatives, a process for the preparation

2,3,4,5-Tetrahydro-1-benzoxepins of the formula I ##STR1## with R.sup.1 equaling, inter alia, H, alkyl, alkoxy, Hal, alkylsulfonyl, arylsulfonyl, R.sup.2 equaling H, alkyl, alkoxy, OH, R.sup.3 to R.sup.6 H or alkyl and X equaling ##STR2## have excellent efficacy as antihypertensives, as coronary therapeutics, as agents for the treatment of cardiac insufficiency, of disturbances of cerebral and peripheral blood flow or of disturbances of intestinal motility, premature labor, obstructions of the airways or of the urinary tract or of the biliary tract or as spasmolytics.

2,3,4,5-tetrahydro-1-benzoxepins, the use thereof and pharmaceutical

Compounds I ##STR1## where R.sup.1 is H, alkyl, alkoxy, CO alkyl, COOH, carboxyalkyl, CONR.sub.2, CN, NO.sub.2, alkylsulfi(o)nyl, arylsulfi(i)-nyl; R.sup.2 is H, OH, alkoxy, alkyl or alkylcarbonyl, R.sup.3 /R.sup.4 are alkyl, m is zero or one and X is --CR.sup.6 .dbd.CR.sup.7 -(--CR.sup.8 .dbd.CR.sup.9) (R.sup.6 R.sup.9 are H or alkyl), where n is zero or 1, are described. They are active antihypertensives and spasmolytics for the bladder, intestine, gall bladder, uterus, trachea and ureter.

Unsaturated N-benzopyranyllactams

Substituted quinoxalyl-imidazolidine-2,4-diones, processes for their preparation, their use as medicaments and pharmaceutical preparations 5-Quinoxalyl-imidazolidine-2,4-diones of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings given, and physiologically tolerated salts thereof and processes for their preparation are described. The compounds inhibit aldose reductase and can be used as medicaments.

Substituted quinoxalyl-imidazolidine-2,4-diones, processes for their

Growing community of inventors

Messel, Germany

Roland Utz